195 related articles for article (PubMed ID: 22258851)
1. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases.
Gao H; Dong B; Jia J; Zhu H; Diao C; Yan Z; Huang Y; Li X
J Cancer Res Clin Oncol; 2012 May; 138(5):753-61. PubMed ID: 22258851
[TBL] [Abstract][Full Text] [Related]
2. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
3. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
Gupta A; Nath K; Bansal N; Kumar M
Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
[No Abstract] [Full Text] [Related]
4. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis.
Gao H; Dong B; Liu X; Xuan H; Huang Y; Lin D
Anal Chim Acta; 2008 Aug; 624(2):269-77. PubMed ID: 18706333
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the metabolomic profile of renal cell carcinoma by high resolution magic angle spinning proton magnetic resonance spectroscopy.
Huynh MJ; Gusev A; Palmas F; Vandergrift L; Berker Y; Wu CL; Wu S; Cheng LL; Feldman AS
Urol Oncol; 2023 Nov; 41(11):459.e9-459.e16. PubMed ID: 37863744
[TBL] [Abstract][Full Text] [Related]
6. (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool.
Zira AN; Theocharis SE; Mitropoulos D; Migdalis V; Mikros E
J Proteome Res; 2010 Aug; 9(8):4038-44. PubMed ID: 20527959
[TBL] [Abstract][Full Text] [Related]
7. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues.
Righi V; Mucci A; Schenetti L; Tosi MR; Grigioni WF; Corti B; Bertaccini A; Franceschelli A; Sanguedolce F; Schiavina R; Martorana G; Tugnoli V
Anticancer Res; 2007; 27(5A):3195-204. PubMed ID: 17970061
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
10. Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC).
Baumunk D; Reichelt U; Hildebrandt J; Krause H; Ebbing J; Cash H; Miller K; Schostak M; Weikert S
World J Urol; 2013 Oct; 31(5):1191-6. PubMed ID: 22544372
[TBL] [Abstract][Full Text] [Related]
11. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
[TBL] [Abstract][Full Text] [Related]
12. [Metabonome in Early Diagnosis of Renal Cell Carcinoma].
Wang Z; Zhang YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Oct; 41(5):709-713. PubMed ID: 31699205
[TBL] [Abstract][Full Text] [Related]
13. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
14. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
15. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
[TBL] [Abstract][Full Text] [Related]
16. Network-based metabolic characterization of renal cell carcinoma.
Pandey N; Lanke V; Vinod PK
Sci Rep; 2020 Apr; 10(1):5955. PubMed ID: 32249812
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of matrix metalloproteinase 2 protein expression in patients with renal cell carcinoma: A case-control study and meta-analysis.
Liu Q; Zhang GW; Zhu CY; Wei JX; Tian X; Li Y; Li XD
Cancer Biomark; 2016; 16(2):281-9. PubMed ID: 26756619
[TBL] [Abstract][Full Text] [Related]
18. Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis.
Rausch S; Beermann J; Scharpf M; Hennenlotter J; Fend F; Stenzl A; Schollenberger D; Bedke J; Kruck S
World J Urol; 2016 Dec; 34(12):1635-1641. PubMed ID: 26995391
[TBL] [Abstract][Full Text] [Related]
19. Role Of Immunohistochemistry In Subtyping Renal Cell Carcinomas With Overlapping Morphological Features.
Tariq N; Mamoon N; Haroon A; Ali Z; Ahmad IN
J Ayub Med Coll Abbottabad; 2018; 30(3):325-332. PubMed ID: 30465359
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
